Clinical Trial

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-19
notable Primary completion moved earlier: 2027-03-31 -> 2026-06-18 2026-07-19
minor Completion moved earlier: 2027-03-31 -> 2026-06-18 2026-07-19
Trial Details
NCT Number NCT04572295
Lead Sponsor Eisai Co., Ltd.
Conditions Breast Neoplasms
Enrollment 51 participants
Start Date 2020-10-09
Primary Completion 2026-06-18 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-17